The immune system responds to an infection by producing antibodies that recognize and bind to the cell surface of the pathogen, thus marking it as an intruder and triggering an immune response. For ...

A new study by LMU and Helmholtz Munich shows how the pathogen Trypanosoma brucei controls changes in its cell surface to evade the immune ...

Discover how the ALA-CART platform enhances CAR T cell efficacy against antigen-low leukemias. With improved LAT activation, ...

This review seeks to familiarize the readers with RSV rapid antigen-detection tests, describe their performance characteristics and comment on their strengths and weaknesses. The authors will ...

Antigenic variation is a key mechanism by which pathogens evade the immune system. New research has shown how trypanosomes change their antigen expression.

Cellogen Therapeutics awaits CDSCO approval for Phase I trials on innovative CAR-T product targeting B cell leukemia.

VUMC has been awarded up to $30 million from the Advanced Research Projects Agency for Health (ARPA-H) to build a massive ...

The Car-T cell therapy was tested on patients with B-cell leukaemia and lymphoma - rare types of blood cancers - that affect the bone marrow and the lymphatic system.